Journal article
892-P: Impact of ReCET Therapy on Continuous Glucose Monitoring (CGM) Metrics in Type 2 Diabetes—Insights from the REGENT-1 Trial
DAVID N O'NEAL, JOHN APOSTOLOPOULOS, ADRIAN SARTORETTO, SUJIEVVAN CHANDRAN, RHYS VAUGHAN, BRONTE HOLT, GEORGINA CAMERON, BARHAM ABUDAYYEH, RICHARD E PRATLEY, CHRISTOPHER H SORLI, ELIF I EKINCI
Diabetes | American Diabetes Association | Published : 2025
DOI: 10.2337/db25-892-p
Abstract
Introduction and Objective: The REGENT-1 trial evaluated the Re-Cellularization via Electroporation Therapy (ReCET™) System, which uses pulsed electric fields (PEF) to regenerate duodenal mucosa and submucosa. We examined the effect of ReCET™ across energy dose cohorts on CGM metrics. Methods: REGENT-1studied endoscopic PEF therapy at three doses in T2D adults on 1-4 non-insulin agents. Group 1) Gen 1 catheter 600V, single treatment (n=12); Group 2) Gen 1 catheter, 600V, double treatment (n=18); and Group 3) Gen 2 catheter (increased treated surface area [TSA]), double treatment 750V (n=21). CGM data were collected using Guardian 3 (Medtronic) Results: Fifty-one..
View full abstract